G17DT - a new weapon in the therapeutic armoury for gastrointestinal malignancy

Bibliography

• KOH TJ, CHEN D: Gastrin as a growth factor in thegastrointestinal tract. Regul. PepL (2000) 93:37–44.
   PubMed Web of Science ®Google Scholar
• MIYAKE A: A truncated isoform of humanCCK-B/gastrin receptor generated by alternative usage of a novel ex on. Biochem. Biophys. Res. Commun. (1995) 208 (1):230–237.
   PubMed Web of Science ®Google Scholar
• MCWILLIAMS DF, WATSON SA, CROSBEE DM, MICHAELID, SETH R: Coexpression of gastrin and gastrin receptors (CCK-B and CCK-B in gastrointestinal tumour cell lines. Gut (1998) 42 (6):795–798.
   PubMed Web of Science ®Google Scholar
• HELLMICH MR, RUT X-L, HELLMICH HL, FLEMING RYD, EVERS BM, TOWNSEND JR CM: Human colorectal cancers express a constitutively active cholecystokinin-B/gastrin receptor that stimulates cell growth. J. Biol. Chem. (2000) 275(40:32122–32128.
   PubMedGoogle Scholar
• GOETZE JP, NIELSEN FC, BURCHARTH F, REHFELD JF: Closing the gastrin loop in pancreatic cancer. Cancer (2000) 88(10:2487–2494.
   PubMedGoogle Scholar
• SMITH AM, WATSON SA: Review article: gastrin and colorectal cancer. Aliment. Pharmacol. Ther. (2000) 14:1231–1247.
   PubMed Web of Science ®Google Scholar
• SMITH AM, WATSON SA: Gastrin and gastrin receptoractivation - an early event in the adenoma-carcinoma sequence. Gut (2000) 47:820–824.
   PubMed Web of Science ®Google Scholar
• HENWOOD M, CLARKE PA, SMITH AM, WATSON SA:Expression of gastrin in developing gastric adenocar-cinoma. Br. J Surg. (2000). (In Press).
   Google Scholar
• KOH TJ, BULITTA CJ, FLEMING JV, DOCKRAY GJ, VARROA, WANG TC: Gastrin is a target of the 13-catenin/TCF-4 growth-signaling pathway in a model of intestinal polyposis.j Clin. Invest. (2000) 106(4):533–539.
   Google Scholar
• MIYAZAKI Y, SHINOMURA Y, TSUTSUI S et al: Gastrininduces heparin-binding epidermal growth factor-like growth factor in rat gastric epithelial cells transfected with gastrin receptor. Gastroenterology (1999) 116:78–89.
   PubMed Web of Science ®Google Scholar
• VIDGREN V, VARIS A, KOKKOLA A et al: Concomitantgastrin and ERBB2 gene amplifications at 17 q12-q21 in the intestinal type of gastric cancer. Genes Chromosomes Cancer (1999) 24:24–29.
   PubMed Web of Science ®Google Scholar
• MACADAM RC, SARELA Al, FARMERY SM, ROBINSON PA, MARKHAM AF, GUILLOU PJ: Death from early colorectal cancer is predicted by the presence of transcripts of the REG gene family. Br. J Cancer (2000) 83(2):188–95.
   PubMed Web of Science ®Google Scholar
• FUKUI H, KINOSHITA Y, MAEKAWA T et al: Regener-ating gene protein may mediate gastric mucosal prolif-eration induced by hypergastrinemia in rats. Gastroenterology (1998) 115:1483–1493.
   PubMed Web of Science ®Google Scholar
• MAKISHIMA R, LARKIN P, MICHAELI D, GAGINELLA TS:Active immunisation against gastrin-17 with an N-terminal derived immunogen inhibits gastric and duodenal lesions in rats. Gastroenterology (1994) 106:A824.
   Google Scholar
• WATSON SA, MICHAELI D, GRIMES S et al.: Gastrimmune raises antibodies that neutralize amidated and glycine-ex tended gastrin-17 and inhibit the growth of colon cancer. Cancer Research (1996) 56:880–885.
   PubMed Web of Science ®Google Scholar
• WATSON SA, MICHAELI D, GRIMES S et al: Anti-gastrin antibodies raised by gastrimmune inhibit growth of the human colorectal tumour AP5. Int. J. Cancer (1995) 61:233–240.
   PubMed Web of Science ®Google Scholar
• GILLIAM A, HENWOOD M, ROWLANDS BJ, BECKINGHAM0, WATSON SA. The ability of G179-DT to raise antibodies to G17 in patients with pancreatic carcinoma. Br. J Surgery (2000). (In Press).
   Google Scholar
• JUSTIN T, WATSON S, MICHAELI D, HARDCASTLE J, STEELE R: Gastric acid suppression using anti-gastrin 17 antibodies produced by a gastrin immunogen, Gastrimmune, in an in vivo pig model. Gastroenterology (1995) 108(4):125.
   PubMedGoogle Scholar
• SMITH AM, MORRIS T, MICHAELI D, WATSON SA: Gastrimmune induced anti-gastrin antibodies inhibit stimulated acid output in a rat gastric fistula model. Gut (1999) 44:379.
   Google Scholar
• WATSON SA, MICHAELI D, JUSTIN TA et al: Pre-clinicalevaluation of the gastrimmune immunogen alone and in combination with 5-fluorouracil/leucovorin in a rat colorectal cancer model. Int. J. Cancer (1998) 75:873–877.
   PubMed Web of Science ®Google Scholar
• WATSON SA, MICHAELI D, MORRIS TM et al: Antibodiesraised by gastrimmune inhibit the spontaneous metastasis of a human colorectal tumour, AP5LV. Eur.J. Cancer (1999) 35(8):1286–1291.
   PubMed Web of Science ®Google Scholar
• WATSON SA, MORRIS TM, CROSBEE DM, HARDCASTLE JD: Anew hepatic invasive human colorectal x enograft model. Eur. J. Cancer (1993) 29A:1740–1745.
   PubMed Web of Science ®Google Scholar
• WATSON SA, SMITH AM, MICHAELI D, GRIMES S, CAPLIN M, HARDCASTLE JD: Antibodies targeting the amino terminal portion of the human CCKB/gastrin receptor inhibit the liver invasion of a human colonic tumour. Gastroenterology (1998) 114(4):G2899.
   Google Scholar
• WATSON SA, MICHAELI D, MORRIS TM, MCWILLIAMS D, SMITH AM: The role of gastrin in the adenoma:carcinoma sequence in the colon. Digestion (1999) 60:25.
   PubMedGoogle Scholar
• WATSON SA, SMITH AM: Hypergastrinaemia promotes adenoma progression in the APCMin1/4mouse model of familial adenomatous polyposis. Cancer Res. (2001). (In Press).
   Google Scholar
• WATSON SA, MORRIS TM, VARRO A, MICHAELI D, SMITH AM: A comparison of the therapeutic effectiveness of gastrin neutralisation in two human gastric cancer models: relation to endocrine and autocrine/paracrine gastrin mediated growth. Gut (1999) 45(6):812–817.
   PubMed Web of Science ®Google Scholar
• WATSON SA, MICHAELI D, GRIMES S et al.: A comparison of an anti-gastrin antibody and cytotoxic drugs in the therapy of human gastric ascites in scid mice. Int. J. Cancer (1999) 81 (2):248–254.
   PubMed Web of Science ®Google Scholar
• AJANI JA: Current status of therapy for advanced gastric carcinoma. Oncology (Huntingt.) (1999) 12 (8S6):99–102.
   Google Scholar
• BRAMHALL SR, ALLUM WH, JONES AG, ALLWOOD A, CUMMINS C, NEOPTOLEMUS JP: Treatment and survival in 13,560 patients with pancreatic cancer and incidence of the disease in the West Midlands: An epidemiological study. Br. J Surg. (1995) 82:111–115.
   PubMed Web of Science ®Google Scholar
• CANCER REGISTRY OF NORWAY: Survival of Cancer Patients. Cases diagnosed in Norway 1968-75. Oslo, Cancer Registry of Norway, (1980).
   Google Scholar
• BRENNAN MF, KINSELLA TJ, CASPER ES: Cancer of the pancreas. In: Cancer: Principles and Practice of Oncology (Edition 4). De Vita VT Jr, Hellman S, Rosenburg SA (Eds.), Lippincott, Philadelphia, (1993).
   Google Scholar
• CARMICHAEL J: Clinical response benefit in patients with advanced pancreatic cancer: role of gemcitabine. Digestion (1997) 58:503–507.
   PubMed Web of Science ®Google Scholar
• SMITH AM, JUSTIN T, MICHAELI D, WATSON SA: Phase study of G17:DT, an anti-gastrin immunogen, in advanced colorectal cancer. Clin. Can. Res. (2001). (In Press).
   Google Scholar
• HENWOOD M, SMITH AM, WATSON SA et al: An open, dose-ranging, multicentre study to determine the antibody response to gastrimmune and it's safety and tolerability in the treatment of patients with gastric cancer. Gut (2000) 46:W163.
   PubMedGoogle Scholar
• GILLIAM AD, HENWOOD M, SMITH AM et al.: A Phase II study of G17DT in gastric carcinoma. Gut (2001). (In Press).
   Google Scholar
• BRETT BT, SMITH SC, BOUVIER CV et al.: APhase II studyof gastrimmune in advanced pancreatic cancer. Gut (2000) 46:17.
   Google Scholar
• GILLIAM A, HENWOOD M, WATSON SA, ROWLANDS BJ,BECKINGHAM IJ: Treatment of advanced pancreatic carcinoma with G17DT. Br. J. Surg. (2001). (In Press).
   Google Scholar